QurAlis to Participate in Upcoming Investor Conferences in September
Tweet
Share
E-mailCAMBRIDGE, Mass.--(BUSINESS WIRE)-- QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that Kasper Roet, Ph.D., CEO and co-founder, will participate at the following investor conferences in September. Management will also participate in one-on-one investor meetings.
| Wells Fargo Securities 21st Annual Healthcare Conference | |
Format: |
Presentation; one-on-one investor meetings |
Date/Time: |
September 10, 2026; 10:15AM ET |
Location: |
Boston, MA |
Morgan Stanley 24th Annual Global Healthcare Conference |
|
Format: |
Presentation; one-on-one investor meetings |
Date/Time: |
September 14, 2026; 2:00PM ET |
Location: |
New York, NY |
H.C. Wainwright 28th Annual Global Investment Conference |
|
Format: |
One-on-one investor meetings |
Date: |
September 15, 2026 |
Location: |
New York, NY |
13th Annual World Medical Innovation Forum |
|
Format: |
Panel: Rare But Not Forgotten / Strategies to Maximize Impact for Rare Disease Patients; one-on-one investor meetings |
Date/Time: |
September 23, 2026; 2:30PM ET |
Location: |
Boston, MA |
Bank of America Healthcare Trailblazers Private Company Showcase Conference |
|
Format: |
One-on-one investor meetings |
Date: |
September 24, 2026 |
Location: |
Boston, MA |
The QurAlis corporate presentation can be accessed by visiting the presentations section of the Company’s website at www.quralis.com.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260818644392/en/
Media contact:
Kathy Vincent
[email protected]
310-403-8951
Source: QurAlis Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concordare Trials Secures Funding Round to Accelerate Digitization of Clinical Trial Protocols
- Solar Lease Experts Expands National Advocacy Services for Landowners Hosting Utility-Scale Solar
- Ivonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Morgan Stanley, Wells Fargo, H.C. Wainwright, BofA/Merrill LynchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
